Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab IV in active ankylosing spondylitis
NCT02186873Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of golimumab in ankylosing spondylitis (AS), sponsored by Janssen Pharmaceutical. Started Sep 2014; status: completed.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02186873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186873.